Sun Pharma to Acquire Organon for $11.75 Billion in Landmark Global Deal

Mega acquisition to propel Sun Pharma into global top tier with expanded footprint in women’s health and biosimilars.

NEW DELHI (India CSR): In a landmark move that underscores India Inc’s growing global ambitions, Sun Pharmaceutical Industries Ltd on Monday announced it will acquire US-based healthcare firm Organon & Co. in an all-cash deal valued at $11.75 billion. The transaction marks one of the largest overseas acquisitions by an Indian company and is expected to significantly strengthen Sun Pharma’s global standing.

The definitive agreement, approved by the boards of both companies, entails Sun Pharma acquiring all outstanding shares of Organon at $14 per share. The deal is slated to close in early 2027, subject to regulatory approvals and shareholder consent.

Market Cheers Strategic Move

Investor sentiment turned sharply positive following the announcement, with shares of Sun Pharmaceutical Industries surging over 7 per cent in early trade. The stock climbed 7.53 per cent to Rs 1,742 on the BSE and 7.50 per cent to Rs 1,742 on the NSE.

The rally added approximately Rs 27,462.59 crore to the company’s market capitalisation, reflecting strong investor confidence in the strategic value of the acquisition.

Transformational Leap in Global Scale

The acquisition of Organon is expected to be transformative for Sun Pharma, enabling it to significantly expand its global footprint and product portfolio. Organon, which was spun off from Merck & Co. in 2021, operates six manufacturing facilities across the European Union and emerging markets.

The US-based firm boasts a diversified portfolio of over 70 products, covering key therapeutic areas such as women’s health, biosimilars, and general medicines. Its products are sold across more than 140 countries, making it a well-established global player.

Following the acquisition, the combined entity is projected to have revenues of approximately $12.4 billion, positioning Sun Pharma among the top 25 pharmaceutical companies worldwide.

Strengthening Presence in High-Growth Segments

A key highlight of the deal is Sun Pharma’s entry into leadership positions in high-growth segments. The company is expected to become a top-three player in the global women’s health market and the seventh-largest biosimilar company worldwide.

Sun Pharma Executive Chairman Dilip Shanghvi described the deal as a strategic milestone. “This transaction represents a significant opportunity for Sun Pharma. Organon’s portfolio, capabilities, and global reach are highly complementary to our own,” he said.

Organon Executive Chair Carrie Cox echoed similar sentiments, stating that the deal offers immediate and compelling value to shareholders. “Sun Pharma is well-positioned to support Organon’s businesses, employees, and patients globally,” she noted.

Financial Strength and Synergy Potential

Organon reported revenues of $6.2 billion for 2025, with an adjusted EBITDA of $1.9 billion. The company carries a debt of $8.6 billion and has cash reserves of $574 million.

Sun Pharma has projected synergies exceeding $350 million within two to four years following the completion of the deal. These synergies are expected to arise from operational efficiencies, expanded market access, and enhanced research and development capabilities.

The combined entity will operate in around 150 countries, with at least 18 markets generating revenues exceeding $100 million each, highlighting the scale and diversification of the merged operations.

Among India’s Largest Overseas Acquisitions

The deal ranks among the most significant cross-border acquisitions by Indian firms. It joins the league of Tata Steel’s $12 billion acquisition of Corus in 2007 and Bharti Airtel’s $10.7 billion purchase of Zain Telecom’s African operations in 2010.

For Sun Pharma, the acquisition continues its track record of strategic expansion through mergers and acquisitions. Notable past deals include the $4 billion takeover of Ranbaxy Laboratories in 2014 and the acquisition of Taro Pharmaceutical Industries in 2007.

Strategic Implications for Indian Pharma

Industry experts view the acquisition as a bold step that reflects the maturity and global competitiveness of Indian pharmaceutical companies. By integrating Organon’s capabilities, Sun Pharma is expected to strengthen its presence in regulated markets while diversifying into high-value therapeutic segments.

The move also aligns with broader trends in the global pharmaceutical industry, where companies are seeking scale, innovation, and geographic diversification to drive growth amid rising competition and regulatory complexities.

You Learn

With regulatory approvals and shareholder consent pending, the deal is expected to close in early 2027. Once completed, it will mark a defining moment for Sun Pharma, elevating it into a new league of global pharmaceutical giants.

The acquisition not only reinforces Sun Pharma’s growth strategy but also signals India’s increasing influence in the global healthcare landscape, as domestic firms continue to pursue ambitious international expansions.

(India CSR)